I am a senior scientist working in clinical and preclinical development of anti-tuberculosis drugs in the group of Prof. Michael Hoelscher, Department of Infectious Diseases and Tropical Medicine (DITM), Ludwig-Maximilians-University of Munich.
I am currently involved in phase I and preclinical evaluation of Q203, a drug candidate developed by the Korean company Qurient, and BTZ043, which is developed by my home institution.
As a sponsor medical expert, I coordinated two clinical trials for new tuberculosis therapies within the PanACEA consortium: the complex innovative multi-arm MAMS study (clinicaltrials.gov NCT01785186) and a previous EBA study (NCT01218217), and a capacity development mock EBA study in two Tanzanian sites.
Further, I manage the group’s TB treatment research activities and capacity development activities in Mbeya, Tanzania.
My second field of interest is research on emerging arthropod-borne diseases, where I am currently heading a study on fever of unknown origin in the Mbeya area.
I am a board accredited specialist in Paediatrics and Adolescent Medicine, which I acquired after work in three German Centers. I am chair of a charitable NGO which is working in healthcare and food security in Malawi.